AJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wiginton, C. D.
Right arrow Articles by Chaljub, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wiginton, C. D.
Right arrow Articles by Chaljub, G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?

Gadolinium-Based Contrast Exposure, Nephrogenic Systemic Fibrosis, and Gadolinium Detection in Tissue

Clark D. Wiginton1, Brent Kelly2, Aytekin Oto3,4, Mary Jesse5, Patricia Aristimuno6,7, Randy Ernst3,8 and Gregory Chaljub1

1 Department of Radiology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555.
2 Department of Dermatology, University of Texas Medical Branch, Galveston, TX.
3 Department of Radiology, University of Texas Medical Branch, Galveston, TX.
4 Present address: Department of Radiology, University of Chicago, Chicago, IL.
5 School of Medicine, University of Texas Medical Branch, Galveston, TX..
6 Department of Nephrology, University of Texas Medical Branch, Galveston, TX
7 Present address: Division of Nephrology, Texas Tech University, Lubbock, TX.
8 Present address: Department of Radiology, M. D. Anderson Cancer Center, Houston, TX.


Figure 1
View larger version (20K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 1 —Over 10-year time course in our local outpatient dialysis clinic population, 83 patients underwent MRI, 72 of whom received MR contrast material. Sixty-three of 72 received gadodiamide, 54 of whom received gadodiamide only and nine also received gadopentetate. Eighteen received gadopentetate, of whom nine received gadopentetate only and nine received gadodiamide also.

 

Figure 2
View larger version (10K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 2 —Both cases of nephrogenic systemic fibrosis (NSF) discovered in our local outpatient dialysis center's population exclusively followed at our institution were diagnosed in our dermatology department and were archived in our dermatopathology database. Five additional cases of NSF were discovered in dermatopathology database, two of which were followed up at dialysis centers in other cities, whereas the other three never required treatment at outpatient dialysis center.

 

Figure 3
View larger version (9K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 3 —Plot of total time to develop nephrogenic systemic fibrosis (NSF) symptoms after onset of gadolinium contrast exposure in renal failure versus cumulative dose of gadolinium-based contrast agent before symptom onset in each patient ({diamondsuit}) shows no linear correlation between two factors (r = 0.01).

 

Figure 4
View larger version (9K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 4 —Chemical structure of gadodiamide. Chelate ligand partially encompasses gadolinium ion. (Courtesy of GE Healthcare)

 

Figure 5
View larger version (8K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 5 —Diagram of possible mechanism of fibrosis in nephrogenic systemic fibrosis (NSF) illustrates points at which various potential risk factors may interact to potentiate development of fibrosis. Note that angiotensin-converting enzyme (ACE) inhibitors may inhibit fibrosis found in NSF. TGF-β = transforming growth factor-β.

 

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Roentgen Ray Society.